Wire · opportunities
Overall Survival Results from the CAPItello-281 Trial of Capivasertib in PTEN-Deficient mHSPC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 November 2026 · Fusion42 review
The CAPItello-281 Phase 3 trial showed that adding capivasertib, an AKT inhibitor, to standard androgen deprivation therapy plus abiraterone significantly improves overall survival and delays symptomatic skeletal events in men with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). The benefit is observed regardless of metastatic volume, highlighting the importance of targeting both androgen receptor and AKT/PI3 kinase pathways in this aggressive cancer subtype.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can no longer rely on metastatic volume to decide treatment intensity in PTEN-deficient prostate cancer. Targeting both hormone and AKT pathways with capivasertib opens a new treatment dimension that changes monitoring and therapeutic choices for this patient group.
◆ Coverage
1 source · 4 Nov 2026
◆ Related on Wire
◆ Topics